CRISPR Therapeutics
CRSP
179 hedge funds and large institutions have $1.01B invested in CRISPR Therapeutics in 2018 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 49 increasing their positions, 40 reducing their positions, and 39 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 49 | Existing positions reduced: 40
13% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 39
5.07% more ownership
Funds ownership: 39.2% → 44.27% (+5.1%)
3% more funds holding
Funds holding: 174 → 179 (+5)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
7% less capital invested
Capital invested by funds: $1.09B → $1.01B (-$78.9M)
57% less call options, than puts
Call options by funds: $20.2M | Put options by funds: $46.7M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$52.4M |
| 2 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$51.7M |
| 3 |
Jennison Associates
New York
|
+$28.3M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
+$26.2M |
| 5 |
Two Sigma Investments
New York
|
+$18.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$13.3M |
| 2 |
Franklin Resources
San Mateo,
California
|
-$12.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$12.5M |
| 4 |
Renaissance Technologies
New York
|
-$10.1M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$8.15M |
CRSP Hedge Fund Activity: Q3 2018 in Review
179 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q3 2018, worth a combined $1.01B — down 7.3% from $1.09B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new CRSP positions and 39 closed out — a net gain of 5 holders — while 49 added to existing stakes and 40 trimmed.
The largest buyer was Waddell & Reed Financial, opening a new position worth an estimated $52.4M. The largest seller was Lord, Abbett & Co, exiting entirely with an estimated $13.3M sold.
- 179 institutional investors held CRISPR Therapeutics (CRSP) as of Q3 2018, up from 174 in Q2 2018.
- Funds reported $1.01B of CRISPR Therapeutics stock for Q3 2018, down 7.3% quarter-over-quarter.
- 44 funds opened new CRISPR Therapeutics positions in Q3 2018 and 39 closed out, a net change of +5 holders.
- The largest CRISPR Therapeutics buyer in Q3 2018 was Waddell & Reed Financial, an estimated $52.4M added.
- The largest CRISPR Therapeutics seller in Q3 2018 was Lord, Abbett & Co, an estimated $13.3M sold.
Based on aggregated 13F filings for Q3 2018.